Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Novartis AG | TREANDA (bendamustine) + MONJUVI (tafasitamab) - (B-MIND) | Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) | Phase 3 | Trial Completed | Intravenous | Oncology |
| Novartis AG | ZOLGENSMA (AVXS-101) - (SPR1NT) | Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3 | Phase 3 | Intravenous infusion | Genetic Disorder | |
| Novartis AG | ENTRESTO (Sacubitril/valsartan) - (PARADISE-MI) | Post-acute myocardial infarction | Phase 3 | Trial Discontinued | Oral | Cardiology |
| Novartis AG | QAW039 (fevipiprant) - (LUSTER-1) | Asthma | Phase 3 | Trial Discontinued | oral | Respiratory |
| Novartis AG | RELAX-AHF-2 (RLX030) | Acute heart failure | Phase 3 | Intravenous | Cardiology | |
| Novartis AG | KISQALI (ribociclib) - (MONALEESA-2) | Breast cancer | Phase 3 | Data Released | oral | Oncology |
| Novartis AG | COSENTYX (secukinumab) - (SURPASS) | Ankylosing spondylitis (AS) | Phase 3 | Subcutaneous | Immunology: Anti-TNF | |
| Novartis AG | Fabhalta (iptacopan) - (APPEAR-C3G) | C3 Glomerulopathy | Phase 3 | Ongoing | Oral | Immunology |
